Citizens JMP Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
Tweet Send to a Friend
Citizens JMP analyst Roy Buchanan reiterated a Market Outperform rating and $5.00 price target on AN2 Therapeutics (NASDAQ: ANTX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
